IP Library Granted Patent US 8,524,779
Granted Patent B2
US 8,524,779 · App. 13/096,512 · Granted Sep 3, 2013

Emulsion compositions containing quaternary ammonium compounds

Inventors: Laura Rabinovich-Guilatti (Kadima, IL); Gregory Lambert (Chatenay Malabry, FR); Frederic Lallemand (Fresnes, FR); Betty Philips (Antony, FR)
Assignee: Novagali Pharma SA
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,779
App. No.
13/096,512
Granted
Sep 3, 2013
Kind
B2
Abstract

Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.

Claims (32)

1. An oil-in-water emulsion comprising:

1% to 5% w/w of an oil phase selected from the group consisting of medium chain triglycerides and mineral oils;

0.0005% to 0.1% w/w of cetalkonium chloride as the sole ammonium halide of the emulsion; and

0.3% w/w of tyloxapol.

2. The oil-in-water emulsion according to claim 1 , wherein the oil phase is medium chain triglycerides.

3. The oil-in-water emulsion according to claim 2 , wherein the amount of medium chain triglycerides is 2% w/w.

4. The oil-in-water emulsion according to claim 1 , wherein the amount of mineral oils is 1% w/w.

5. The oil-in-water emulsion according to claim 1 , wherein the oil phase is mineral oils, said mineral oils being a mixture of heavy mineral oil and light mineral oil wherein the ratio of heavy mineral oil to light mineral oil is equal to 1:1.

6. The oil-in-water emulsion according to claim 5 , wherein the amount of light mineral oil is 0.5% w/w and the amount of heavy mineral oil is 0.5% w/w.

7. The oil-in-water emulsion according to claim 1 , wherein the amount of cetalkonium chloride is 0.001% to 0.02% w/w.

8. The oil-in-water emulsion according to claim 1 , wherein the amount of cetalkonium chloride is selected from the group consisting of 0.001%, 0.0025%, 0.005%, 0.01%, 0.02%, 0.04% and 0.1% w/w.

9. The oil-in-water emulsion according to claim 1 , further comprising poloxamer 188.

10. The oil-in-water emulsion according to claim 9 , wherein the amount of poloxamer 188 is 0.1% w/w.

11. The oil-in-water emulsion according to claim 1 , further comprising buffering agents and/or at least one tonicity agent.

12. The oil-in-water emulsion according to claim 11 , wherein the tonicity agent is mannitol.

13. The oil-in-water emulsion according to claim 11 , wherein the tonicity agent is glycerol.

14. The oil-in-water emulsion according to claim 1 , said emulsion having a positive zeta potential.

15. The oil-in-water emulsion according to claim 1 , said emulsion having a droplet size of 100 to 500 nm.

16. The oil-in-water emulsion according to claim 1 , said emulsion being hypotonic, relative to normal tears.

17. The oil-in-water emulsion according to claim 1 , wherein said emulsion is in the form of a gel suitable for ophthalmic use.

18. An oil-in-water emulsion comprising:

0.5% w/w of light mineral oil;

0.5% w/W of heavy mineral oil;

0.002% w/w of cetalkonium chloride;

0.3% w/w of tyloxapol; and

0.1% w/w of poloxamer 188,

wherein the cetalkonium chloride is the sole ammonium halide of the composition.

19. An oil-in-water emulsion comprising:

1% to 2% w/w of medium chain triglycerides;

0.005% to 0.02% w/w of cetalkonium chloride;

0.3% w/w of tyloxapol; and

0.1% w/w of poloxamer 188, wherein the cetalkonium chloride is the sole ammonium halide of the composition.

Assignments (3)
CHANGE OF ADDRESS Recorded Feb 20, 2025
From: SANTEN
To: SANTEN
Reel/Frame 070276/0582 →
CHANGE OF NAME Recorded Feb 25, 2014
From: NOVAGALI PHARMA SA
To: SANTEN SAS
Reel/Frame 032332/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2013
From: RABINOVICH-GUILATT, LAURA; LAMBERT, GREGORY; LALLEMAND, FREDERIC; PHILIPS, BETTY
To: NOVAGALI PHARMA SA
Reel/Frame 030376/0266 →
Priority Claims (3)
EP 06291236.5 · Jul 28, 2006 · regional
EP 07112097.6 · Jul 9, 2007 · regional
WO PCT/IB2007/053441 · Jul 10, 2007 · international
Continuity (3)
Continuation 11829428 · Jul 27, 2007
Continuation In Part 11494493 · Jul 28, 2006
Related Publication 20110201689A1 · Aug 18, 2011